期刊
FRONTIERS IN PHARMACOLOGY
卷 10, 期 -, 页码 -出版社
FRONTIERS MEDIA SA
DOI: 10.3389/fphar.2019.00112
关键词
GRK2; GPCR; cardiovascular; obesity; NAFLD; insulin resistance; inhibitors
资金
- Ministerio de Economia
- Industria y Competitividad (MINECO) of Spain [SAF2017-84125-R, SAF2016-80305-P]
- CIBERCV-Instituto de Salud Carlos III, Spain [CB16/11/00278, CB16/11/00286]
- European FEDER
- Programa de Actividades en Biomedicina de la Comunidad de Madrid [B2017/BMD-3671-INFLAMUNE, B2017/BMD-3676-AORTASANA]
G protein-coupled receptor kinase 2 (GRK2) is a central signaling node involved in the modulation of many G protein-coupled receptors (GPCRs) and also displaying regulatory functions in other cell signaling routes. GRK2 levels and activity have been reported to be enhanced in patients or in preclinical models of several relevant pathological situations, such as heart failure, cardiac hypertrophy, hypertension, obesity and insulin resistance conditions, or non-alcoholic fatty liver disease (NAFLD), and to contribute to disease progression by a variety of mechanisms related to its multifunctional roles. Therefore, targeting GRK2 by different strategies emerges as a potentially relevant approach to treat cardiovascular disease, obesity, type 2 diabetes, or NAFLD, pathological conditions which are frequently interconnected and present as co-morbidities.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据